The document analyzes primary and secondary prevention strategies deployed in ongoing EU funded personal health systems projects, commercial products, websites, and public health campaigns. It finds that initiatives focus mainly on specific diseases or risk factors in isolation, with little interoperability. Secondary prevention experiences outnumber primary prevention initiatives. Successful business models are often simple consumer products rather than complex solutions for primary prevention. Most solutions involve individuals and sometimes healthcare systems, but reduced participation from other actors in a co-creator model of health.
Business Model Innovation in Healthcare by Chris WasdenMatt Perez
Rapid technological advances, regulatory reform, and the new science of personalized medicine are the three primary factors driving unprecedented levels of innovation in the healthcare industry. These factors are forcing convergence among all members of the healthcare ecosystem in ways that enable all members to create greater value through extensive coordination, collaboration, and competition. Increasingly, providers, payers, products, and patients are leveraging mobile information technology to participate in M2M (mobile-to-mobile) digital healthcare delivery. Some of the key questions facing healthcare organizations, and particularly their CIOs, are: Where in the healthcare innovation ecosystem should we focus? What types of innovations create the most value for our organization? How do we enable greater levels of innovations from a strategic, process, and infrastructure perspectives? What are the barriers to developing and adopting innovation in the healthcare industry, and within healthcare organizations, and how do we overcome these barriers?
Business Model Innovation in Healthcare by Chris WasdenMatt Perez
Rapid technological advances, regulatory reform, and the new science of personalized medicine are the three primary factors driving unprecedented levels of innovation in the healthcare industry. These factors are forcing convergence among all members of the healthcare ecosystem in ways that enable all members to create greater value through extensive coordination, collaboration, and competition. Increasingly, providers, payers, products, and patients are leveraging mobile information technology to participate in M2M (mobile-to-mobile) digital healthcare delivery. Some of the key questions facing healthcare organizations, and particularly their CIOs, are: Where in the healthcare innovation ecosystem should we focus? What types of innovations create the most value for our organization? How do we enable greater levels of innovations from a strategic, process, and infrastructure perspectives? What are the barriers to developing and adopting innovation in the healthcare industry, and within healthcare organizations, and how do we overcome these barriers?
Telemedicine in the Current New Normal: Opportunities and BarriersDr. Mustafa Değerli
Değerli, M. and Özkan-Yıldırım, S. (2021). Telemedicine in the Current New Normal: Opportunities and Barriers. Enhanced Telemedicine and e-Health: Advanced IoT Enabled Soft Computing Framework – Springer. 10.1007/978-3-030-70111-6_2 - https://link.springer.com/chapter/10.1007/978-3-030-70111-6_2
Enablers for IoT regarding Wearable Medical Devices to Support Healthy Living...Dr. Mustafa Değerli
Değerli, M. and Özkan-Yıldırım, S. (2021). Enablers for IoT regarding Wearable Medical Devices to Support Healthy Living: The Five Facets. IoT in Healthcare and Ambient Assisted Living – Springer. 10.1007/978-981-15-9897-5_10 - https://link.springer.com/chapter/10.1007/978-981-15-9897-5_10
Healthcare Innovation Now: 3 themes and 10 insights.frog
frog’s Executive Creative Director Fabio Sergio builds a strong case at Mobile Health Industry Summit 2011 in Brussels about why healthcare solutions should be ecosystem-based and designed around people, not "just" patients.
This is a prescriptive / generic roadmap for telemedicine, that can be used by Governments , NGOs, companies & individuals in deploying telemedicine and mHealth solutions.
This roadmap was developed by a global team of 17 experts led by Rajendra Pratap Gupta under the Innovation Working Group -Asia (IWG-A).
IWG-A was set up by the office of the UN Secretary General to harness the power of innovations for Health , specially for health related MDGs.
More details write to ea2rajendragupta@gmail.com
Chronic illness: 75% of health system costs in North America
* Reimbursement models & care pathways focused
on disease management will continue to escalate
iStart - eHealth Vital signs for the future of health technologyHayden McCall
From referrals systems to electronic health records and
devices that allow patients to monitor their symptoms,
health sector technology is evolving. Chris Bell
asks if providers are making things better for healthcare
professionals and patients…
Just 70 years ago, politicians claimed
to know more about what was good
for our health than we did ourselves.
These days it seems Google is more
likely to be consulted than the family doctor.
To Dr Sarah Dods, research leader of health services
at CSIRO (the Commonwealth Scienti ic and
Industrial Research Organisation) in Victoria, health
is the last bastion of a pre-industrial world: people
making local decisions and doing things their own
way because they believe that’s best. “There’s a
centuries-old culture around the art-form of diagnosis
and the intuition a doctor is required to have to
do their job. The way they’ve been trained is a very
di ferent model from quality assurance and industrialised
principles.”
What your organisation needs to know about personal health budgets, communica...CharityComms
Jaimee Lewis, Think Local, Act Personal
Changing the game: positioning your charity to succeed in the new health service market conference
www.charitycomms.org.uk/events
Digital therapeutics and immersive technologies Bournemouth UniversityDavid Wortley
Digital therapeutics is a fast growing area of digital medicine. In this presentation, Vice President of the International Society of Digital Medicine (ISDM), David Wortley, sets out the current challenges to global health sustainability and the importance of shifting the focus from cure to prevention, especially in the use of digital technologies for personal health management and therapeutics.
The presentation includes examples of digital therapeutic applications for neuro- rehabilitation, gamified exercise using consumer VR devices and support for dementia sufferers through digital memories.
The presentation was delivered at the new Faculty for Health and Social Sciences at Bournemouth University.
Theera-Ampornpunt N. Quality and regulatory compliance in health care. Presented at: Faculty of ICT, Mahidol University; 2012 Mar 13; Bangkok, Thailand.
Enquête mondiale conduite par l’Economist Intelligence Unit (EIU) pour PwC sur l'adoption généralisée de la technologie mobile dans le domaine de la santé, ou m-Santé.
Retrouvez toutes nos publications : http://www.pwc.fr/publications
Telemedicine in the Current New Normal: Opportunities and BarriersDr. Mustafa Değerli
Değerli, M. and Özkan-Yıldırım, S. (2021). Telemedicine in the Current New Normal: Opportunities and Barriers. Enhanced Telemedicine and e-Health: Advanced IoT Enabled Soft Computing Framework – Springer. 10.1007/978-3-030-70111-6_2 - https://link.springer.com/chapter/10.1007/978-3-030-70111-6_2
Enablers for IoT regarding Wearable Medical Devices to Support Healthy Living...Dr. Mustafa Değerli
Değerli, M. and Özkan-Yıldırım, S. (2021). Enablers for IoT regarding Wearable Medical Devices to Support Healthy Living: The Five Facets. IoT in Healthcare and Ambient Assisted Living – Springer. 10.1007/978-981-15-9897-5_10 - https://link.springer.com/chapter/10.1007/978-981-15-9897-5_10
Healthcare Innovation Now: 3 themes and 10 insights.frog
frog’s Executive Creative Director Fabio Sergio builds a strong case at Mobile Health Industry Summit 2011 in Brussels about why healthcare solutions should be ecosystem-based and designed around people, not "just" patients.
This is a prescriptive / generic roadmap for telemedicine, that can be used by Governments , NGOs, companies & individuals in deploying telemedicine and mHealth solutions.
This roadmap was developed by a global team of 17 experts led by Rajendra Pratap Gupta under the Innovation Working Group -Asia (IWG-A).
IWG-A was set up by the office of the UN Secretary General to harness the power of innovations for Health , specially for health related MDGs.
More details write to ea2rajendragupta@gmail.com
Chronic illness: 75% of health system costs in North America
* Reimbursement models & care pathways focused
on disease management will continue to escalate
iStart - eHealth Vital signs for the future of health technologyHayden McCall
From referrals systems to electronic health records and
devices that allow patients to monitor their symptoms,
health sector technology is evolving. Chris Bell
asks if providers are making things better for healthcare
professionals and patients…
Just 70 years ago, politicians claimed
to know more about what was good
for our health than we did ourselves.
These days it seems Google is more
likely to be consulted than the family doctor.
To Dr Sarah Dods, research leader of health services
at CSIRO (the Commonwealth Scienti ic and
Industrial Research Organisation) in Victoria, health
is the last bastion of a pre-industrial world: people
making local decisions and doing things their own
way because they believe that’s best. “There’s a
centuries-old culture around the art-form of diagnosis
and the intuition a doctor is required to have to
do their job. The way they’ve been trained is a very
di ferent model from quality assurance and industrialised
principles.”
What your organisation needs to know about personal health budgets, communica...CharityComms
Jaimee Lewis, Think Local, Act Personal
Changing the game: positioning your charity to succeed in the new health service market conference
www.charitycomms.org.uk/events
Digital therapeutics and immersive technologies Bournemouth UniversityDavid Wortley
Digital therapeutics is a fast growing area of digital medicine. In this presentation, Vice President of the International Society of Digital Medicine (ISDM), David Wortley, sets out the current challenges to global health sustainability and the importance of shifting the focus from cure to prevention, especially in the use of digital technologies for personal health management and therapeutics.
The presentation includes examples of digital therapeutic applications for neuro- rehabilitation, gamified exercise using consumer VR devices and support for dementia sufferers through digital memories.
The presentation was delivered at the new Faculty for Health and Social Sciences at Bournemouth University.
Theera-Ampornpunt N. Quality and regulatory compliance in health care. Presented at: Faculty of ICT, Mahidol University; 2012 Mar 13; Bangkok, Thailand.
Enquête mondiale conduite par l’Economist Intelligence Unit (EIU) pour PwC sur l'adoption généralisée de la technologie mobile dans le domaine de la santé, ou m-Santé.
Retrouvez toutes nos publications : http://www.pwc.fr/publications
Talk entitled "from the Virtual Human to a Digital Me" presented at the Virtual Physiological Human 2012 Conference held at IET Savoy, Savoy Place, London, 18-20 September 2012.
Sickness Funds and the Pharmaceutical Industry: a New Relationship?Beapp_Bcpm
On Friday 3rd March, Dr Jan Van Emelen, Innovation Director at Neutral Mutualities presented on “Mutualities and pharmaceutical industry: a new relationship?”. Access to new, often very expensive medications is a hot topic and our speaker discussed the role of the mutualities in this process, using new models for disease management. He shared ideas on our potential interaction with this process as pharmaceutical physicians.
Karen Day, University of Auckland
Koray Atalag, University of Auckland
Denise Irvine, e3health
Bryan Houliston, Auckland University of Technology
(4/11/10, Illott, 1.45)
Peter J. Murray RN, PhD, MSc, CertEd, FBCS CITP
CEO, International Medical Informatics Association (IMIA) and Director, CHIRAD Africa
(3/11/10, Illott, 4.00)
This presentation shows that doctors are increasingly using mobile health for:
•Mobile, text and video-based consultations
•Patient monitoring
•Accessing patient data
•Explaining to patients their conditions and medical information
•Increased efficiency, for example saving time in receiving test results or consulting with colleagues or administration.
However for many m-Health is changing the doctor-patient relationship. The doctors’ traditional role is being disrupted while patients are becoming more independent and more active in managing their own healthcare.
Telemedicina i pacients crònics / Telemedicine in chronic patientsAntoni Parada
Telemedicina i pacients crònics. Conferència impartida pel Professor canadenc Denis Protti Health Information Science - Victoria University. Barcelona, 2 de febrer de 2012. Organitzada per la Fundació TicSalut i l’Agència d’Informació, Avaluació i Qualitat en Salut.
E health in Nigeria Current Realities and Future Perspectives. A User Centric...Ibukun Fowe
In this era of the digital revolution, innovative computer software programs and Information and communications technologies (ICTs) are disrupting different industries of most economies and the healthcare sector is one of the nascent and emerging opportunities for technology disruption and innovation. This is an “inevitable” welcome development as Global health innovation is at the forefront of embracing the use of technology solutions in various parts of the world to improve access to health services and medicines, and Nigeria is not to be an exception. This symposium is focused on asking the fundamental questions; how much impact are e-health applications making in the Nigerian health sector and how do we improve the level of impact and
effectiveness of these applications via a user-centric approach?
Taking these proactive steps serve to ensure that we focus on the real needs of the Nigerian people and put in place quality and safety measures that will give users the confidence needed to use e-health applications and solutions adequately and appropriately. This symposium invites key-stakeholders in the e-health
ecosystem to share their views on the pains and gains of e-health as of today and how to shape the future of e-health in Nigeria (and similar countries). Some of the presentations and panelist sessions will include real field experience and user-centered qualitative research that will elicit the current level of impact and the real needs of e-health users in the southwest region of Nigeria.
Personal Profile, Motivation, User SegmentationPREVE group
Identified different factors influencing health behavior and behavior change:
– Determinants of reasoned behavior
– Habits and systematic biases
– Life stages and trigger events
– Environmental contexts
– Effective health communication
Review high‐level intervention strategies
Tentative plan for profiling and user segmentation
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Best Ayurvedic medicine for Gas and IndigestionSwastikAyurveda
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...Oleg Kshivets
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
CDSCO and Phamacovigilance {Regulatory body in India}
PREVE project overview - months 1-6
1. Directions for ICT Research in Disease Prevention
FP7-ICT-2009.5.1 – Support Action
PREVE Overview
Project Months 1-6
Niilo Saranummi
VTT Technical Research Centre of Finland
This project is partially funded under the 7th Framework Programme by the European Commission
3. PREVE – in brief
• A 12 month Support Action, under the 4th FP7 ICT Call
• Four partners
• Objective
– Identify ICT research directions for the empowerment of citizens
in disease prevention and the preservation of health
www.preve-eu.org
4. What PREVE delivers
Impact
• White Paper identify ICT research directions for the empowerment of
citizens in disease prevention and the preservation of health
highlighting the need to approach disease prevention from multiple
complementary viewpoints.
• Articles offered to peer-reviewed journals and to conferences in order
to target different stakeholders in disease prevention
www.preve-eu.org
5. PREVE impact
• “PREVE will suggest ICT research directions in primary
prevention.
– Thus it will open a new avenue of research in the PHS where the
so far traditional concept “a physician in the loop” does not
always apply and the participation of the healthcare sector may
be indirect.
– The lead idea of the project is “having the individual as a co-
producer of health” and empowering individuals to take
responsibility of their health with personalised ICT enabled PHS
technologies and services.
– In this way the project paves the way towards a health service
environment where individuals and health professionals work
jointly towards health goals.”
www.preve-eu.org
8. Prevention is the best strategy
• According to WHO,
– 77% of the disease burden in Europe is accounted for by disorders
related to lifestyles. Furthermore, 70% of stroke and colon cancer,
80% of coronary heart disease, and 90% of type II diabetes could
be prevented by maintaining healthy lifestyles.
• The best prevention strategy is to lead a healthy lifestyle.
• But, although we are constantly “bombarded” with health
promotion information that we should exercise regularly,
eat healthy, control our weight, sleep enough, manage
stress, not smoke and use alcohol only moderately etc. as
a population we are not doing a good job in acting
according to this advice.
www.preve-eu.org
9. Clearly, people need assistance
• Based on this it should be clear that we as individuals
need assistance in primary prevention.
• The questions are
– What kind of assistance and
– How the assistance should be made available / offered and
– How to ensure that the assistance provides effective help to the
individual in changing and maintaining her lifestyle.
www.preve-eu.org
10. Health behaviours,
Personalization, Environment
Co-
producer ICT in Disease Prevention
network
Networked business models
Prevention of diseases Value proposition, validation
HOW
PREVENTABLE DISEASES ICT ENABLED PRIMARY PREVENTION
www.preve-eu.org
11. PREVE workflow – 3 phases
Where we are now
Barcelona Workshops Milan
16.3.2010 8.11.2010
Belfast
14.6.2010
M9 31.11.2010
1.12.2009
Select the User White paper
Business ICT Research
diseases & segments &
models and Directions in
best Personal
validation Primary
practices profiles Prevention
(T3.1 – 3)
(T2.1) (T2.2 – 4) (T3.4)
www.preve-eu.org
12. Workflow in more detail
Personas
Demand (WP2, Completed)
Preventable Clinical risk Health Personal Intervention
diseases factors behaviours profiling needs
Co- Individual +
Co-creators
producers Environment
”My Health Business Value Business Brokering of
Project” cases proposition models best fit
Supply (WP3, WIP)
www.preve-eu.org
13. Directions for ICT Research in Disease Prevention
FP7-ICT-2009.5.1 – Support Action
WP2 – Analysis of the Domain
Vicente Traver
Universidad Politécnica de Valencia
vtraver@upvnet.upv.es
This project is partially funded under the 7th Framework Programme by the European Commission
14. WP2 goal
General objective:
TO PERFORM AN IN-DEPTH ANALYSIS OF
THE DOMAIN OF PERSONAL HEALTH
SYSTEMS (PHS) IN PREVENTION
www.preve-eu.org
15. WP2 Original specific objectives
To analyze in-depth and refine the framework for PREVE project and of the target
domain: boundaries, concepts, basic facts and benchmarking of ongoing
initiatives in primary prevention and in PHS.
To describe the intervention model for primary prevention considering the citizen
as a co-producer of health.
To assess the different and similar characteristics of the different population
groups that could benefit from primary prevention PHS.
To specialize the basic intervention model with the different population groups
generating a matrix of intervention models for different user segments.
To discuss and refine the findings in two expert workshops
www.preve-eu.org
16. Tasks
T2.1 Selection of diseases and analysis of best practices in their
prevention, incl. lifestyle management & modification (M1-M4)
T2.2 Analysis of primary and secondary prevention strategies
deployed in ongoing EU funded PHS projects and of the market
place (M1-M6)
T2.3 Personal profile, motivation, user segmentation (M1-M6)
T2.4 User segmented intervention strategies (M1-M7)
www.preve-eu.org
17. WP2 alignment within PREVE
Workshops
Barcelona Milan
16.3.2010 8.11.2010
WP2
Belfast
14.6.2010
31.11.2010
1.12.2009
Select the User White paper
Business ICT Research
diseases & segments &
models and Directions in
best Personal
validation Primary
practices profiles Prevention
(T3.1 – 3)
(T2.1) (T2.2 – 4) (T3.4)
www.preve-eu.org
18. WP2 Outputs and milestones
1st PREVE Workshop, March 16th, 2010, and Advisory
Panel Meetings in Barcelona, March 15th and 16th.
D2.1 Selection of the D2.2 Selection of the
relevant diseases and their relevant diseases and their
prevention strategies prevention strategies (final
(draft) (M3) version) (M4)
1st milestone
www.preve-eu.org
19. WP2 Outputs and milestones
2nd PREVE Workshop, June 14th, 2010, and Advisory
Panel Meetings in Belfast, June 13th and 14th.
D2.3 User segmented D2.4 User segmented
intervention strategies intervention strategies
(draft) (M6) (final version) (M7)
2nd milestone
www.preve-eu.org
20. Lessons learnt
• The most prevalent preventable non-communicable
diseases are all lifestyle related
• Relationship disease-disorder risk factor
• Through prevention, scientific evidence of impact on risk
factors
• Citizen as health co-producer
• The citizen has the responsibility to manage her health
and wellbeing
www.preve-eu.org
21. Lessons learnt
• A 3D framework for health behaviour and behaviour
change has been constructed based on a thorough
analysis of existing theories, best practices and other
ongoing initiatives
• Tailoring vs segmentation. Segmentation only valid when
resources for intervention implementation are low and
the targeted behaviours are relatively simple
• Personas description to illustrate the process of profiling
and choosing intervention strategies
www.preve-eu.org
22. Directions for ICT Research in Disease Prevention
FP7-ICT-2009.5.1 – Support Action
Task 2.1 - The Citizen as Co-producer of Health &
Conceptual Framework for Chronic Disease
Niels Boye
University of Aarhus, Denmark
This project is partially funded under the 7th Framework Programme by the European Commission
23. The Citizen as Co-producer of Health –
enabled by ICT
Health Service Delivery
Citizen as proactive subject
Client Centred Approach Citizen as co-Producer of
Patient Centred Medicine Health
Disease prevention
Disease compensation
Model &
Concepts
(Disease cure)
Assisted living
Maturity of ICT
User as Operator
Expert Systems User as User
Contemporary Layman Systems
Corporate Centred State of the Art Ambient Assisted Living Individual Centred
in ICT and
Empowerment
Citizen as object
www.preve-eu.org
24. The “Present Terrain”
“Biological age” (“years”)
Demand side 100 AAL
Supply side
0 100 %
(100% Patient
Citizen)
Tele
Prevention
med
0
www.preve-eu.org
25. The Future.........
“Biological age” (“years”)
100
Chronic
Preven- AAL Tele-
Disease
tion medicine
Management
and
D D
Lifestyle
(100%
Patient
Citizen) D D
100 %
0
0
Society Hospital
www.preve-eu.org
26. Conceptual Aims of “the Citizen as
Co-producer of Health Model"
• Information and patients as resources
• Nature, Nurture, and collaboration with institutionalized
health care
• Personalized management of prevention (and care of
chronic diseases) – in a citizen context
• Multilevel ICT-modeling of health and disease
encapsulated in to personal devices –
Personal Guidance Services (PGS)
From: “Background document for the Consultation meeting
on potential European Large scale Action (ELSA) on eHealth”
European Commission “ICT for Health Unit, H1, 28.08.2009
www.preve-eu.org
27. The Personal Guidance System
• Is a ICT device: based on computer-models of healthy- and
preventive-behaviour, achievable evidence-based
pathways of cure, compensation, or treatment for disease
related conditions
• The Personal Guidance System contains computer-models
for navigation in health similar to the GPS that contains a
model of geography and possibilities in travel
• The PGS provides the personal context of health related
decisions and is the ICT-platform for the “Citizen as Co-
producer of Health”.
www.preve-eu.org
28. Decision support
information flows
Data - and
Clinical Information
encounter flow
EHR
HMO/ Research/
Region Pharmaceutical Co Health-PGS
Quality (digital avatar)
Assurance
Healthcare
Co-production
Research Hospital Patient-NGO
www.preve-eu.org
29. Decision Support
Present service model
• Contemporary service model (provider push) of
prevention:
• Non-specific lifestyle modifications
• Primary prevention (e.g. immunisations)
• Secondary prevention – (e.g. screening programs)
• Tertiary prevention of complications to disease
www.preve-eu.org
30. Prevention in the Co-Producer Model
context
• From the citizen and co-production of health point of view
there is no distinction between primary, secondary and
tertiary prevention
• It is behaviour planning and execution on the basis of
personal-context, evidence-, and knowledge-driven ICT-
augmented decisions
www.preve-eu.org
31. Evidence Based Associations between Risk
Factors and Conditions
Diseases and Disorders Risk Factors
Type 2-diabetes Tobacco smoking
Preventable cancer Alcohol consumption
Cardiovascular disease Diet
Osteoporosis Physical activity
Musculoskeletal disorders Obesity
Hypersensitivity disorders Accidents
Mental disorders Working environment
Chronic obstructive pulmonary disease Environmental factors
www.preve-eu.org
32. Co-production of Disease Prevention
Connections between Risk Factors and Conditions
Citizen Modifiable Risk Factors
Tobacco smoking Conditions
Citizen Modifiable Risk Factors
Type 2-diabetes
Alcohol consumption
Preventable cancer
Diet
Cardiovascular disease
Physical inactivity
Osteoporosis
Obesity
Non-Modifiable Risk Factors Musculoskeletal disorders
Accidents
Hypersensitivity disorders
Working environment
Mental disorders
Environmental factors
Chronic obstructive
pulmonary disease
Family history and gender
www.preve-eu.org
33. Directions for ICT Research in Disease Prevention
FP7-ICT-2009.5.1 – Support Action
Task 2.2 – Analysis of primary and secondary
prevention strategies deployed in ongoing EU
funded PHS projects and of the market place
Teresa Meneu
UPVLC Universidad Politécnica de Valencia
This project is partially funded under the 7th Framework Programme by the European Commission
34. Objectives
Revision of research projects of ICT and
primary prevention
Revision of commercial products, websites and
online health promotion organizations
Revision of complementary domains:
secondary and tertiary prevention, marketing
Revision of public health campaigns
www.preve-eu.org
35. Main Figures
Focus of the prevention projects
40%
35%
30%
25%
20%
15%
10%
5%
0%
www.preve-eu.org
36. Main Figures
Focus of the prevention websites
20%
18%
16%
14%
12%
10%
8%
6%
4%
2%
0%
www.preve-eu.org
37. Main Figures
Type of products
18
16
14 4
12
10 Other products
8
1 Videogames
6 12
4 3 7 2
6
2 3 3
2 2 2
0
www.preve-eu.org
38. Main Figures
Most Common Risk Factors
50%
45%
40%
35%
30%
25% Projects
20%
Websites /
15%
Organizations
10%
5%
0%
Diet Physical Obesity Others
inactivity
www.preve-eu.org
39. Public Health Campaigns
Dietary
Habits,
Tobacco Alcohol Physical Melanoma Vaccination Drugs
Activity &
Obesity
www.preve-eu.org
40. www.preve-eu.org
On PREVE website it has been created a database to collect all
related works: websites, products and projects, focused on
prevention of diseases and risk factors.
www.preve-eu.org
42. Conclusions
Isolation of initiatives
• Little signs of interoperability either on a technical or at a conceptual level.
• The original purpose of the projects is mainly focused in a specific domain and was not expecting to be used or
profited in conjunction with others.
The number of secondary prevention experiences is much bigger that those of primary
prevention
• More mature market
• More well defined conditions
• More funding allocated to this domain
• They could provide some useful information related mainly to motivation
• Not applicable to the same extent to business models or technological solutions.
General lack of sustainable trustable business models linked to primary prevention
• Most successful initiatives are very simple and sold as ’consumer’ products, for leisure, pleasure or beauty .
• Interesting models linked to some healthcare initiatives: Kaiser, Mayo Clinic, Healthvault, Google Health,
Reduced participation of multiple actors in the co-creator model, most solutions have only
the individual and, in some cases, the healthcare system.
www.preve-eu.org
43. Conclusions
Reduced presence of external influences (society, family, etc) in the picture
besides the initiatives linked to web 2.0.
Interesting results in peer motivation and support in similar domains that
could be applied to primary prevention.
The most apparently successful results are based in the physical activity
domain.
General awareness of main risk factors and potential diseases, aligned with
the results of D2.2.
Reduced support to practical implementation of strategies but much more
provision of semi-personalized guidelines.
Most projects just do population based personalization (segmentation) and
some tailoring based in a few set of individual parameters (i.e. BMI).
www.preve-eu.org
44. Directions for ICT Research in Disease Prevention
FP7-ICT-2009.5.1 – Support Action
Task 2.3 – Personal profile, motivation,
user segmentation
Kirsikka Kaipainen
VTT Technical Research Centre of Finland
Kirsikka.Kaipainen@vtt.fi
This project is partially funded under the 7th Framework Programme by the European Commission
45. Objectives
• To analyze different motivation strategies proposed in literature and
implemented in current activities that are or could be applied to
lifestyle management and modification, especially drawing from the
experience in advertising and marketing
• To assess the cultural and socio-economic issues that could affect the
effectiveness of the identified motivation strategies
• To analyse user segmentation based on life stages
• To develop the concept of personal profile based on life stages, risk
factors, motivation and socioeconomic factors
• A segmentation analysis over the population groups highlighted in
task 2.1 for the different diseases, based in the different dimensions
that could influence the intervention model
• To match the identified motivation strategies with the user
segmentation produced in T2.3
www.preve-eu.org
47. Determinants of health behaviour
• Various theories and frameworks were investigated
– Psychological theories about individual behaviour and
stages of behaviour change
– Theories of values and motivation
– Developmental theories
– Communication theories
– Social marketing theories
– Behavioural economics
– Cognitive-behavioural therapies and persuasive
technologies
The theories overlap and complement each other
– There is no one theory that completely explains behaviour
and behaviour change
– A hybrid model to include essential factors and their
relationships is needed
www.preve-eu.org
48. Determinants of health behaviour
Values, Social
influences Ability
personality,
life stages
Reasoned
Awareness Self-efficacy Intention
Public policy behaviour
Community
Outcome Barriers
expectations
Organizational
Automatic
behaviours
Interpersonal Environmental contexts
Individual
www.preve-eu.org
52. Principles of interventions
• Primary aims:
– Create or strengthen intention through other determinants
– Increase abilities and remove barriers
• Guiding principles:
– Provide immediate, tangible, personally valuable benefits for
healthy behaviours
– Frame health-promoting messages in an appealing manner
– Guide people with appropriate choice architectures
– Take advantage of trigger events
– Make changes on multiple levels by involving different actors
– Identify co-creators of health and involve them in interventions
www.preve-eu.org
53. PROFILE
Monitor trigger
Risk factors events and profile
Values & motivators updates
Resources
Channels Assess current Health behaviour
Current behaviours Diet
Physical Activity
Alcohol consumption OK, no Support
Smoking current risks behaviour/
Stress maintenance
Sleep
Mental well-being
Risky/poor,
Choosing
need for behaviour change
Identify
determinants to
appropriate
target
Intention per
Lack of resources
Strengthen
interventions
Evaluate progress, Strong (external, actual
behaviour? resources
outcomes and profile abilities)?
updates
Weak or nonexistent
Not aware of risks Discouraging social Unfavourable outcome
and benefits / Weak self-efficacy?
environment? expectations?
misconceptions?
Strengthen social
Improve self- Improve outcome
Educate independence /
efficacy and skills expectations
increase support
Execute the Select methods & tailor
intervention the intervention
Personal characteristics
Problem
Values & motivators characteristics
Personal resources
Co-creators
Social environment
Service environment
Physical environment
www.preve-eu.org
54. Personalization of interventions
• Targeting vs. tailoring
– Targeting: designing interventions for subgroups with common
characteristics
– Tailoring: fitting an intervention to meet the personal needs and
characteristics of a person rather than a group
• The most effective approach, but traditionally costly
• ICT could enable deeply personalized, cost-efficient
interventions
– A Do-It-Yourself (DIY) platform for profiling yourself and to select
interventions that match your profile
– Means for data entry, assessment, monitoring, context-
awareness, feedback personal guidance and motivation
www.preve-eu.org
55. Directions for ICT Research in Disease Prevention
FP7-ICT-2009.5.1 – Support Action
Task 2.4 – User Segmented Intervention
Strategies
Teresa Meneu
UPVLC Universidad Politécnica de Valencia
This project is partially funded under the 7th Framework Programme by the European Commission
56. Main Objectives
To put together the collected
information from the previous tasks by:
• Defining the primary prevention intervention
model and differentiating its main dimensions.
• Describing the disease – best intervention
strategies matrix of T2.1 with personalization data
resulting in a user segmented disease – best
intervention strategies matrix.
• Concluding the work in WP2 in valuable outcomes
for the next phase of research.
www.preve-eu.org
57. Main Inputs
T2.4 Intervention Logic
and Profile
Draft Primary Prevention
Intervention Model &
PERSONA’s
WP3
www.preve-eu.org
58. Primary Prevention Intervention Model
DIY
Profiler
Broker
Analyze Plan
Trigger
event
Evaluate Execute
PGS
PHS
www.preve-eu.org
59. Personalized Primary Prevention
Intervention Model
DIY Which is the risk
Profiler of the individual? Broker
How to select/choose
the intervention
Analyze Plan
strategy?
Trigger
event
Evaluate Execute
PGS
How to assess the PHS How to put it in practice in
evolution and provide the concrete
readjustments? time/location/need?
www.preve-eu.org
60. Personalized Intervention Strategies
Profiling Matrix
Health behaviors Segments that would
(and intention) benefit from behavior
maintenance interventions
No risk Segments in need of
lifestyle change with
Low risk different levels of urgency
Examples of possibly
unrealistic segments
high
High risk Resources
low
Motivators
Life Stages
www.preve-eu.org
61. Profiling Matrix Dimensions
Health behaviour is any activity undertaken by an individual which
influences health outcomes.
• Regardless of actual or perceived health status, the intention can be promoting,
protecting or maintaining health, but the attitudes and behaviours can also be harmful,
unsafe and damaging to health.
Motivation must be present for a lifestyle change to happen and it
has much to do about sustainability of the change.
• The motivation refers to the reason or reasons for engaging in a particular behaviour
and it may be intrinsic, extrinsic or both.
The Resources are the tools present in the environment surrounding
the individual at his disposal to carry out an interactive action.
• There are internal and external resources and they can have a positive or negative
influence in the intervention.
www.preve-eu.org
63. From Profiling to Personalized Intervention
Tailoring
Profiling
Personalized
Intervention
www.preve-eu.org
64. Monitor trigger
PROFILE events and profile
Risk factors
updates
Values & motivators
Resources Assess current Health behavior
Channels Diet
Current behaviors Physical Activity
Alcohol consumption OK, no Support behavior/
current risks maintenance
Smoking
Stress
Sleep
Mental Wellbeing
Student, motivated, healthy habits: She is a female.
Risky/poor,
need for behavior change
She is 20 years old and a student. She lives in a city
Identify
determinants to
1. Student
Strengthen
and with her boyfriend. Her main values are:
Yes
target resources
achievement, security, power and self-direction.
Evaluate progress,
outcomes and profile
Intention per
behavior?
Strong
Lack of resources
(external or actual
abilities)? 3. Middle age
updates overdoing
2. Corporate
Weak or nonexistent
wellness
Strengthen social
Intervention
Discouraging social
Yes independence /
environment?
increase support
Logic Aware of risks 5. Young old
and benefits? person
Improve self-
Weak self-efficacy? Yes
efficacy and skills
Not aware /
Male Adult, unmotivated, using services of
Misconceptions
7. Obese child
4. Housewife
community wellness: He is a male. He is 34 years Unfavourable outcome
expectations?
Yes
Improve outcome
expectations
old and employed. He lives in a city with his wife.
6. Community
wellness
His main values are: security, tradition and
Educate
Execute the
intervention
benevolence. Select methods & tailor
the intervention
Personal characteristics
Values & motivators Problem
Personal resources characteristics
Co-creators
Social environment
Service environment
Physical environment
www.preve-eu.org
65. Conclusions
COMPLEXITY OF THE DOMAIN
• Specially in relation to the human nature and its natural
reluctance to change a preferred, well established health
behaviour, and the incredible high amount of factors and
dimensions that need and must be considered to design an
effective primary prevention intervention model.
• This scenario poses a set of challenges where ICT technologies
could definitively play a significant role:
• acquiring the required information
• tracing the evolution and changes of the person, its context
and her risk profile
• processing the enormous set of information to create
practical decision support tools for the individuals.
www.preve-eu.org
66. Conclusions
FULL PERSONALIZATION
• Designing effective and sustainable primary prevention strategies
is a very personal issue, even for similar risk profiles, the optimal
way to manage to reduce or overcome said risk presents different
faces depending on the concrete individual.
• Different moments of life, different situations or events, present
or past, would imply an instant need to recalibrate the
intervention strategy as the things that were effective in the past
may no longer be applicable.
• The large number of relevant health determinants shows that
interventions need to be tailored in order to meet the personal
needs and characteristics of a person. In segmentation
compromises would have to be made that would limit the
potential success of the interventions.
www.preve-eu.org
67. Conclusions
ICT ENABLING MULTILEVEL STRATEGIES
• The number of theories is large but yet no one has proven to
be the most suitable for all individuals and all situations.
• Different scenarios may need a different approach or even a
combination of those.
• The inclusion of ICT technologies into the picture and the way
it would affect the behaviours has not been extensively
studied or validated and could cause differences in the efficacy
on the different theories.
• The use of ICT to support the interventions could dramatically
change the limitations and boundaries that current
intervention models have in relation to the selection or one or
another strategy for behaviour change.
www.preve-eu.org
68. Conclusions
PREVENTION ECOSYSTEM
• Inclusion of third parties in the intervention cycle: co-
creators
• Some of the co-creators will truly interact with the
individual in co-creating health. Others will participate
through the choice architectures and defaults that
they set through policies and other actions.
• The influence of the environment is very strong and is
dynamically present in the prevention model.
• Co-creators need to be accommodated into the
intervention strategies.
www.preve-eu.org
69. Directions for ICT Research in Disease Prevention
FP7-ICT-2009.5.1 – Support Action
Outlook
Months 7 – 12
Niilo Saranummi
VTT Technical Research Centre of Finland
This project is partially funded under the 7th Framework Programme by the European Commission
70. Completion of 3rd phase
Workshops
Barcelona Milan
16.3.2010 8.11.2010
Belfast
14.6.2010
31.11.2010
1.12.2009
Select the User White paper
Business ICT Research
diseases & segments &
models and Directions in
best Personal
validation Primary
practices profiles Prevention
(T3.1 – 3)
(T2.1) (T2.2 – 4) (T3.4)
www.preve-eu.org
73. The health-co-production ECO-system
Three layer ICT Business Model
• “App store” - Library of applications
for managing health behaviours.
– Built by community research and
innovation
– Maintained and certified by Patient-NGO’s
– NEW business opportunity for SMEs
• Platform(s) for ICT-services.
– Built and maintained by enterprise
vendors.
– Specified and tested by EC in a (major)
CIP-like project
• The interoperability and security
layer.
– Specified by Standards and Directives.
www.preve-eu.org
74. Co-producers / co-creators
of health
personal trainers, restaurants, food markets, school,
workplace, media, healthcare professionals ...
www.preve-eu.org
75. The environment matters
”Preloading” to create favourable conditions
Society
”upstream”
Communities
Organizations
Friends
Individual & family
”downstream”
www.preve-eu.org
76. Examples of business cases
who ”owns” the customer
• Worried well & Fitness
– Individuals pay out of their own pocket
– Third party life insurance companies are interested
• Corporate wellness
– The company makes H&W services available to employees
– Reduction in insurance premiums (sickness, retirement)
• Society – policies
– School wellness programs
• Integrated care providers (e.g. Kaiser Permanente)
– If prevention is the best strategy it will be in the interest of IC providers to
keep patients out of hospitals
• Health-related consumer goods & service industries
– Food & beverage
– Sports & fitness
– Media & edutainment
– Consumer electronics
www.preve-eu.org
77. PREVE specific impacts
• Facilitating the development of prospective aspects of ICT-enabled prevention
of diseases
– “White Paper” – ICT research directions
• Reduced hospitalisation and improved disease management and treatment at
the point of need, through more precise assessment of health status
– Proactive health management, i.e. Primary prevention
• Economic benefits for health systems without compromising quality of care
– Freeing scarce resources to the care of the ill
• Reinforced leadership and innovation of the industry in the area of Personal
Health Systems and medical devices. New business models for health service
providers and insurance sectors
– Health behaviours, Personalization, Networked business models, N = 1, …
• Improved links and interaction between patients and doctors facilitating more
active participation of patients in care processes
– Co-creator network, Individual + Environment
• Accelerating the establishment of interoperability standards and of secure,
seamless communication of health data between all involved partners,
including patients
– Continua, HL7 contacts
www.preve-eu.org
78. PREVE partners
Valtion teknillinen tutkimuskeskus, VTT
Aarhus University
Fondazione Centro San Raffaele del
Monte Tabor
Universidad Politécnica de Valencia